In a fourth phase II study, including 115 ES patients treated with the humanized anti-IGF1R antibody robatumumab, PET-CT revealed six patients with partial response, 23 with stable disease, and 55 with progression of disease after two months [109]. This evidence concerns the gene IGF1R and Ewing sarcoma.